Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13916682 | 0.84 | KDM4E (0.69) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL13916685 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL30971085 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL25680955 | 0.79 | CHRNB2 (0.55) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL862261 | 0.78 | KDM4E (0.62) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL297992 | 0.76 | KDM4E (0.60) | KDM4EALDH1A1LMNAMAPTRAD52 | |
| SCHEMBL521102 | 0.76 | KDM4E (0.55) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL28392846 | 0.75 | KDM4E (0.58) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL10642137 | 0.75 | ALOX15 (0.59) | KDM4EALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL15233270 | 0.75 | KDM4E (0.58) | KDM4EALDH1A1LMNACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228072-B1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RES DEV CO (IL) | 2005-09-28 | — | — | EP | disclosed |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040132725-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | LEVITZKI ALEXANDER (IL) | 2004-07-08 | — | — | US | disclosed |
| US-6673798-B2 | PLATELET DERIVED GROWTH FACTORS (PDGF); 1,2-DIMETHYL-6-(2-THIOPHENE)IMIDAZOLO(5,4-G)QUINOXALINE PREPARATIONS FOR EXAMPLE; USE TREATING PROLIFERATIVE MALIGNANT AND NON-MALIGNANT DISEASES; STENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-01-06 | — | — | US | disclosed |
| US-6656940-B2 | Treatment of cancer. | SUGEN, INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1228072-A4 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RES DEV CO (IL) | 2003-05-07 | — | — | EP | disclosed |
| EP-1036067-A4 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS | YISSUM RES DEV CO (IL) | 2002-10-23 | — | — | EP | disclosed |
| EP-1228072-A1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2002-08-07 | — | — | EP | disclosed |
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6358954-B1 | IMIDAZO(4,5-G)QUINOXALINE DERIVATIVES; ANTITUMOR, ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-03-19 | — | — | US | disclosed |
| US-20020028817-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2002-03-07 | — | — | US | disclosed |
| US-6329375-B1 | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | SUGEN, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2001034607-A1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-05-17 | — | — | WO | disclosed |
| EP-1036067-A2 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem (IL) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028304-A9 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS | YISSUM RES DEV CO (IL) | 1999-09-16 | — | — | WO | disclosed |
| US-5932580-A | TYRPHOSTIN DERIVATIVES | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-08-03 | — | — | US | disclosed |
| WO-1999028304-A2 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | KDM4E 1597/4885ALDH1A1 3484/4885LMNA 3816/4885 |
| US-20020028817-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | PDGFRB, PDGFRA, PDGFA | KDM4E 2256/4885ALDH1A1 4292/4885LMNA 3811/4885 |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | KDM4E 1597/4885ALDH1A1 3484/4885LMNA 3816/4885 |
| US-20040132725-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | PDGFRB, PDGFRA, PDGFA | KDM4E 2256/4885ALDH1A1 4292/4885LMNA 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.